CASI Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CASI research report →
Companywww.casipharmaceuticals.com
CASI Pharmaceuticals, Inc. , a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
- CEO
- David A. Cory
- IPO
- 1996
- Employees
- 233
- HQ
- Beijing, MD, US
Price Chart
Valuation
- Market Cap
- $2.33M
- P/E
- -0.03
- P/S
- 0.08
- P/B
- -0.06
- EV/EBITDA
- -0.39
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 35.80%
- Op Margin
- -167.98%
- Net Margin
- -183.93%
- ROE
- 358.32%
- ROIC
- -1157.47%
Growth & Income
- Revenue
- $28.54M · -15.77%
- Net Income
- $-39,258,000 · -45.73%
- EPS
- $-2.56 · -26.73%
- Op Income
- $-39,621,000
- FCF YoY
- -32.67%
Performance & Tape
- 52W High
- $3.09
- 52W Low
- $0.14
- 50D MA
- $0.86
- 200D MA
- $1.44
- Beta
- 0.89
- Avg Volume
- 225.20K
Get TickerSpark's AI analysis on CASI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Huang James | other | 0 |
| Mar 18, 26 | Huang James | other | 10,000 |
| Mar 18, 26 | Huang James | other | 10,000 |
| Mar 18, 26 | Huang James | other | 101,571 |
Our CASI Coverage
We haven't published any research on CASI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CASI Report →